Workflow
益肺健脾颗粒
icon
Search documents
恩威医药股份有限公司 关于控股股东、持股5%以上股东部分股份质押及解除质押的公告
关于控股股东、持股5%以上股东部分股份质押及解除质押的公告 本公司及董事会全体成员保证信息披露内容的真实、准确、完整,没有虚假记载、误导性陈述或重大遗 漏。 一、股东股份质押基本情况 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码:301331 证券简称:恩威医药 公告编号:2025-055 恩威医药股份有限公司 ■ 上述股东及其一致行动人累计质押股份数量占其所持公司股份数量比例超过50%,现就相关情况说明如 下: 1、本次股份质押不用于满足上市公司生产经营需求; 2、恩威集团及其一致行动人未来半年内到期的累计质押股份数量为14,140,836股,占其所持公司股份的 19.89%,占公司总股本的13.74%,对应融资余额为16,000万元;未来一年内到期的累计质押股份数量为 54,420,836 股,占其所持公司股份的76.54%,占公司总股本的52.89%,对应融资余额为55,600万元。公 司及其一致行动人具备相应的资金偿还能力,还款资金来源为自有及自筹资金。 3、截至本公告披露日,上述股东及其一致行动人不存在非经营性资金占用、违规担保等侵害上市公司 利益的情形; 4、上述股东及其一致行动人股 ...
恩威医药(301331.SZ):子公司取得换发的《药品生产许可证》
Ge Long Hui A P P· 2025-11-26 08:49
格隆汇11月26日丨恩威医药(301331.SZ)公布,全资子公司河南信心药业有限公司(简称:信心药业) 于近日取得了药品监管部门换发的《药品生产许可证》。人参养荣膏、益肺健脾颗粒两个品种已完成委 托、受托生产的许可证换发,尚需河南信心药业有限公司完成生产地址变更及关联变更的备案后方能投 入生产。 ...
6月9日晚间重要公告一览
Xi Niu Cai Jing· 2025-06-09 10:15
Group 1 - Kaichun Co., Ltd. adjusted the share repurchase price limit from 26.625 yuan/share to 40 yuan/share, effective from June 10, 2025 [1] - Yipin Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, a Class 3 chemical drug used for sedation during anesthesia [1] - Bohui Innovation obtained a medical device registration certificate for HPV Genotyping Test Kit, used for qualitative detection of HPV DNA [1][2] Group 2 - Lingyi Zhi Zao's application for issuing convertible bonds and cash payment to acquire 66.46% of Jiangsu Kedasiteng Automotive Technology Co., Ltd. has been accepted by the Shenzhen Stock Exchange [3] - Kemin Food reported a 23.06% year-on-year increase in pig sales in May, with a total of 48,300 pigs sold [4][5] - Meian Sen decided to terminate the issuance of shares to specific objects due to market conditions and strategic considerations [6][7] Group 3 - Zhengbang Technology reported a 146.6% year-on-year increase in pig sales revenue in May, totaling 731 million yuan [9] - Yuanda Holdings plans to reduce the registered capital of its subsidiary from 73 million to 24.3 million USD to optimize asset structure [10] - East China Pharmaceutical's subsidiary received FDA approval for clinical trials of HDM1010 tablets for type 2 diabetes [12] Group 4 - Liangxin Co., Ltd. received a government subsidy of 14.1 million yuan, accounting for 4.52% of its audited net profit for 2024 [13] - Erkang Pharmaceutical's Vitamin B6 Injection passed the consistency evaluation for generic drugs [14] - New Industry received a patent certificate for an antibody related to anti-PIC detection, enhancing detection efficiency [16][15] Group 5 - Dongxing Medical signed a 6 million yuan technology development contract with Shanghai Jiao Tong University for collagen preparation processes [16] - Suchang Chai A's subsidiary will absorb and merge another subsidiary, adjusting internal equity structure [17] - Yibin Technology received a project designation notice from a domestic new energy vehicle company, with an estimated total sales of 256 million yuan over five years [18] Group 6 - Mingchen Health received a cash dividend of 20 million yuan from its subsidiary [19] - Hendi Pharmaceutical obtained a drug registration certificate for Ibuprofen Suspension, a common medication for children [19] - Huaren Pharmaceutical's subsidiary received a drug registration certificate for Dexmedetomidine Hydrochloride Injection, classified as a Category B drug under national medical insurance [20] Group 7 - Enwei Pharmaceutical obtained a renewed drug production license for six key products [21] - Xiaoming Co., Ltd. reported a 45.59% year-on-year increase in chicken product sales in May, totaling 23.25 million birds [23][24] - Shan Natural Gas successfully issued a 350 million yuan short-term financing bond with a 1.78% interest rate [25] Group 8 - Xidamen announced plans for board members to reduce their holdings by up to 581,000 shares [26] - Shentong Technology's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Saintno Bio plans to distribute a cash dividend of 0.14 yuan per share and a capital increase of 0.4 shares per share [28] Group 9 - *ST King Kong's subsidiary received a debt transfer notice from its controlling shareholder, totaling 364 million yuan [29] - Foxit Software's executives plan to reduce their holdings by a total of 55,800 shares [30] - Youyou Green Energy plans to apply for a bank credit line of up to 1.5 billion yuan [31] Group 10 - Guoxing Optoelectronics plans to distribute a cash dividend of 0.5 yuan per 10 shares [32] - Guangxun Technology plans to distribute a cash dividend of 2.6 yuan per 10 shares [33] - Hanrui Cobalt plans to distribute a cash dividend of 1.5 yuan per 10 shares [35] Group 11 - Tigermed plans to distribute a cash dividend of 3 yuan per 10 shares [37] - Shenliang Holdings plans to distribute a cash dividend of 1.5 yuan per 10 shares [38] - Yishitong plans to distribute a cash dividend of 1 yuan per 10 shares [39]